Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Heparin Market

U.S. Heparin Market Size

Report ID: GMI4868
Published Date: Nov 2020
Report Format: PDF

Download Free Sample

U.S. Heparin Market Size

U.S. Heparin Market size exceeded USD 623 million in 2019 and is poised to grow at over 7.2% CAGR between 2020 and 2026. Increasing patient pool suffering from chronic illness and rising demand for anticoagulant products will drive the market growth.

U.S. Heparin Market

To get key market trends

Download Free Sample

Heparin is primarily used in blood transfusion, deep vein thrombosis and kidney dialysis, among others. For instance, according to the National Kidney Foundation report, more than 37 million (15%) individual of U.S. adults are affected by chronic kidney disease (CKD). The report also stated that CKD causes more deaths than breast cancer or prostate cancer. It is one of the under-recognized public health crises. This indicates that there will huge number of patient pool suffering from such disease. Such high prevalence of the disease will increase the heparin market demand in the U.S.

U.S. Heparin Market Report Attributes
Report Attribute	Details
Base Year:	2019
U.S. Heparin Market Size in 2019:	USD 623.2 Million
Forecast Period:	2020 to 2026
Forecast Period 2020 to 2026 CAGR:	7.2%
2026 Value Projection:	USD 1,048.4 Million
Historical Data for:	2015 to 2019
No. of Pages:	66
Tables, Charts & Figures:	37
Segments covered:	Product, Application and Distribution Channel
Growth Drivers:	Growing prevalence of chronic disease High demand for anticoagulant products Rising geriatric population in U.S.
Pitfalls & Challenges:	High risk of side effects High dependency on porcine

Learn more about the key segments shaping this market

Download Free Sample

Heparin is an essential anticoagulant drug that are used in critical life-saving surgical procedures. Thus, it can be expected that the COVID-19 outbreak will not directly impact on the manufacturing of products. However, there can be logistical disruptions especially due to the high reliance on Chinese manufacturing. This could disrupt the supply system of heparin and may cause temporary shortages. This can potentially increase the price of heparin API.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Driven by a rising patient pool suffering from chronic illness coupled with increasing demand for anticoagulant products, the U.S. industry size of heparin surpassed USD 623 million in 2019 and is set to expand at more than 7.2% CAGR through 2026.

The low molecular weight heparin segment revenue in the U.S. was over USD 535.4 million in 2019 and is poised to grow substantially owing to its distinct biochemical and pharmacological properties.

The venous thromboembolism segment accounted for USD 328 million in 2019 and is likely to grow at a 6.8% rate through 2026 favoured by the rising number of patients requiring heparin for treatment of venous thromboembolism.

The hospital pharmacy segment held a market share of 54.3% in 2019, and the rising preference of patients towards hospitals due to ease of availability of medicines will boost the market growth.